Induction of Angiogenesis by Genetically Modified Human Umbilical Cord Blood Mononuclear Cells

Area of Science:

• Regenerative Medicine
• Gene Therapy
• Vascular Biology

Background:

• Angiogenesis stimulation is crucial for treating ischemia-related diseases.
• Umbilical cord blood (UCB) is a promising cell source for transplantation.
• Gene-engineered cells offer a novel strategy for therapeutic angiogenesis.

Purpose of the Study:

• To investigate the therapeutic potential of gene-engineered umbilical cord blood mononuclear cells (UCB-MC) for activating angiogenesis.
• To assess the efficacy of modifying UCB-MC with adenoviral vectors encoding therapeutic genes.

Main Methods:

• Isolated UCB-MC and transduced them with adenoviral vectors (Ad-VEGF, Ad-FGF2, Ad-SDF1α, Ad-EGFP).
• Evaluated in vitro transfection efficiency, gene expression, and secretome profile.
• Assessed angiogenic potential in vivo using a Matrigel plug assay.

Main Results:

• Efficient simultaneous modification of UCB-MC with multiple adenoviral vectors was achieved.
• Modified UCB-MC demonstrated overexpression of recombinant genes and proteins without altering inflammatory profiles.
• Gene-engineered UCB-MC significantly induced new vessel formation, confirmed by CD31 marker expression and histological analysis.

Conclusions:

• Gene-engineered UCB-MC can be effectively modified to overexpress therapeutic genes.
• This approach stimulates angiogenesis and shows potential for treating cardiovascular diseases and diabetic cardiomyopathy.